Characterization and Physical Stability of Tolfenamic Acid-PVP K30 Solid Dispersions

REFERENCES

• Pentikainen P.J., Neuvonen P.J., Backman C. Human Pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent. Eur. J. Clin. Pharmacol 1981; 19(5)359–365
   PubMed Web of Science ®Google Scholar
• Linden I.B., Parantainen J., Vapaatalo H. Inhibition of prostaglandin biosynthesis by tolfenamic acid invitro. Scand. J. Rheumatol 1976; 5(3)129–132
   PubMed Web of Science ®Google Scholar
• Andersen K.V., Larsen S., Alhede B., Gelting N., Buchardt O. Characterization of two polymorphic forms of tolfenamic acid, N-(2-Methyl-3chloriphenyl)anthranilic acid: Their crystal structures and relative stabilities. J. Chem. Soc. Perkin Trans. 1989; 2: 1443–1447
   Google Scholar
• Gilpin R.K., Zhou W. Infrared studies of the polymorphic states of the fenamates. J. Pharm. Biomed. Anal 2005; 37(3)509–515
   PubMed Web of Science ®Google Scholar
• Pedersen S.B. Biopharmaceutical aspects of tolfenamic acid. Pharmacol. Toxicol 1994; 75(2)22–32
   PubMedGoogle Scholar
• Rozou S., Antoniadou-Vyza E. An improved HPLC method overcoming Beer's law deviations arising from supramolecular interactions in tolfenamic acid and cyclodextrins complexes. J. Pharm. Biomed. Anal. 1998; 18(4–5)899–905
   PubMed Web of Science ®Google Scholar
• Vavia P.R., Adhage N.A. Freeze-dried inclusion complexes of tolfenamic acid with B-cyclodextrins. Pharm. Dev. Technol 1999; 5(4)571–574
   Web of Science ®Google Scholar
• Masters K. Spray Drying in Practice. SprayDryConsult International Aps, Charlottenlund, Denmark, 2002
   Google Scholar
• mbike A.A., Mahadik K.R., Paradkar A. Stability study of amorphous valdecoxib. Int. J. Pharm. 2004; 282(1–2)151–162
   PubMedGoogle Scholar
• Yu L. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv. Drug Deliv. Rev 2001; 48(1)27–42
   PubMed Web of Science ®Google Scholar
• Hancock B.C., Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci 1997; 86(1)1–12
   PubMed Web of Science ®Google Scholar
• Jolley J.E. Microstructure of photographic gelatin binders. Photogr. Sci. Eng 1970; 14(3)169–177
   Google Scholar
• Hancock B.C., Shamblin S.L., Zografi G. Molecular mobility of amorphous pharmaceutical solids below their glass-transition temperatures. Pharm. Res 1995; 12(6)799–806
   PubMed Web of Science ®Google Scholar
• Yoshioka M., Hancock B.C., Zografi G. Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J. Pharm. Sci 1995; 84(8)983–986
   PubMed Web of Science ®Google Scholar
• Chen R., Tagawa M., Hoshi N., Ogura T., Okamoto H., Danjo K. Improved dissolution of an insoluble drug using a 4-fluid nozzle spray-drying technique. Chem. Pharm. Bull 2004; 52(9)1066–1070
   PubMed Web of Science ®Google Scholar
• Khougaz K., Clas S.D. Crystallization inhibition in solid dispersions of MK-0591 and poly(vinylpyrrolidone) polymers. J. Pharm. Sci 2000; 89(10)1325–1334
   PubMed Web of Science ®Google Scholar
• Matsumoto T., Zografi G. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinylacetate) in relation to indomethacin crystallization. Pharm. Res 1999; 16(11)1722–1728
   PubMed Web of Science ®Google Scholar
• Van den Mooter G., Wuyts M., Blaton N., Busson R., Grobet P., Augustijns P., Kinget R. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur. J. Pharm. Sci 2001; 12(3)261–269
   PubMed Web of Science ®Google Scholar
• Hancock B.C., Zografi G. The relationship between the glass-transition temperature and the water-content of amorphous pharmaceutical solids. Pharm. Res 1994; 11(4)471–477
   PubMed Web of Science ®Google Scholar
• Ahlneck C., Zografi G. The molecular-basis of moisture effects on the physical and chemical-stability of drugs in the solid-state. Int. J. Pharm. 1990; 62(2–3)87–95
   Web of Science ®Google Scholar
• Bühler V. Kollidon, Polyvinylpyrrolidone for the Pharmaceutical Industry 4th. BASF, Ludwigshafen, Germany, 1999
   Google Scholar
• Nielsen A.F., Bertelsen P., Kristensen H.G., Kristensen J., Hovgaard L. Investigation and comparison of performance of effervescent and standard pneumatic atomizer intended for soluble aqueous coating. Pharm. Dev. Technol 2006; 11(2)243–253
   PubMed Web of Science ®Google Scholar
• Corrigan O.I., Crean A.M. Comparative physicochemical properties of hydrocortisone-PVP composites prepared using supercritical carbon dioxide by the GAS anti-solvent recrystallization process, by coprecipitation and by spray drying. Int. J. Pharm. 2002; 245(1–2)75–82
   PubMedGoogle Scholar
• Paradkar A., Ambike A.A., Jadhav B.K., Mahadik K.R. Characterization of curcumin-PVP solid dispersion obtained by spray drying. Int. J. Pharm. 2004; 271(1–2)281–286
   PubMed Web of Science ®Google Scholar
• Tantishaiyakul V., Kaewnopparat N., Ingkatawornwong S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int. J. Pharm 1999; 181(2)143–151
   PubMed Web of Science ®Google Scholar
• Broman E., Khoo C., Taylor L.S. A comparison of alternative polymer excipients and processing methods for making solid dispersions of a poorly water soluble drug. Int. J. Pharm 2001; 222(1)139–151
   PubMedGoogle Scholar
• Doherty C., York P. Evidence for solid-state and liquid-state interactions in a furosemide polyvinylpyrrolidone solid dispersion. J. Pharm. Sci 1987; 76(9)731–737
   PubMed Web of Science ®Google Scholar
• Damian F., Blaton N., Desseyn H., Clou K., Augustijns P., Naesens L., Balzarini J., Kinget R., Van den Mooter G. Solid state properties of pure UC-781 and solid dispersions with polyvinylpyrrolidone (PVP K30). J. Pharm. Pharmacol 2001; 53(8)1109–1116
   PubMed Web of Science ®Google Scholar
• Taylor L.S., Langkilde F.W., Zografi G. Fourier transform Raman spectroscopic study of the interaction of water vapor with amorphous polymers. J. Pharm. Sci 2001; 90(7)888–901
   PubMed Web of Science ®Google Scholar
• Crowley K.J., Zografi G. Water vapor absorption into amorphous hydrophobic drug/poly(vinylpyrrolidone) dispersions. J. Pharm. Sci 2002; 91(10)2150–2165
   PubMed Web of Science ®Google Scholar